ESPR on the 120-minute chart is surging with momentum from an FDA approval for a new
cholestrol and lipid medication which will be an alternative to the at statin class which has
side effects and can cause diabetes. I am familar with a few of the professionals on the
science advisory board they are researchers and academics of the highest claiber. The chart
shows price testing and getting support from the mean VWAP and a little bit of resistance
from the first upper VWAP line. I have added to my existing position at the consolidation at
VWAP. I am well informed on ESPR market prospects; this could be disruptive.
The dual time frame RSI of Chris Moody has curled up and validates the idea. My interim
target is the double top of this past winter. I do expect increasing volume in time with the
price action that follows.
Disclaimer This a hot penny stock highly volatile - you could lose on this trade. Do not trade
with money you cannot afford to lose. You must manage the trade well to realize profit.
There are options if the put to call ratio is rising big money is pushing a reversal
Comment
⋅
Nice action today. 25% of the position is closed.
Trade active
⋅
More volatility buying and selling zig zag fashion
Trade active
⋅
Price has ran up more than 20%- and is now in the upper VWAP bands and the upper boundary of the Donchain channel. I am watching for an exit signal. The forecasting algo suggests it is coming in the next few trading sessions.